Error in Key Points and Table 1

In the Original Investigation titled “Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial,”¹ published online December 19, 2024, and in the February 2025 issue, there were errors in the Key Points and Table 1. In the Key Points Findings section, the percentage of patients with macrovascular invasion was updated to 74%. In Table 1, the values in the HCC volume/liver volume row were updated to percentages. This article was corrected online.